The global demand for affordable and accessible medicines continues to be shaped by structural inequities in healthcare financing, fragmented supply systems, and a growing burden of both communicable and non communicable diseases. For Balaxi Pharmaceuticals, these dynamics are not abstract macroeconomic forces they are the defining context for every market in which the company operates.
Across Latin America and other frontier markets access to medicines remains constrained by underfunded public health systems, limited insurance penetration, and high out of pocket expenditures. Rural and peri urban communities face the greatest access barriers, where healthcare services are often fragmented and supply chains are weak. These structural conditions sustain persistent demand for affordable, high availability medicines supplied through reliable channels.
| 1 | 2 | 3 | 4 |
| 108 countries representing 83% of global population are classified as LMICs \u2014 the primary markets for affordable medicines | 1.1 billion people across these countries lack access to essential health services | Out of pocket health expenditure in Latin America ranges from 30% to 50% of total health spending, compared to 13% in high income countries | Only 61% of essential medicines are available in public health facilities in LMICs |
Source: Access to Medicine Foundation - Access to Medicine Index 2024; WHO Global Health Observatory; Pan American Health Organization (PAHO)
Frontier Markets including Angola face a dual disease burden the persistence of traditional infectious diseases alongside a rapid rise in non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, and certain cancers. In Latin America, urbanisation, dietary changes, and ageing populations have accelerated NCD prevalence, demanding long term pharmacological treatments that are often unavailable or unaffordable.
| 1 | 2 | 3 | 4 |
| 83 diseases and conditions are prioritised in the Access to Medicine Index due to their prevalence in LMICs | 39 are non communicable diseases including cardiovascular, cancer and diabetes \u2014 all requiring long term medicines | Cardiovascular diseases are among the top three causes of death in most Latin American countries | 44 are communicable, maternal, neonatal and nutritional (CMNN) diseases \u2014 sustaining demand for essential antibiotics and anti infectives |
Source: Access to Medicine Foundation - Access to Medicine Index 2024; WHO Global Health Observatory; PAHO Health in the Americas 2023
While several non-product-registration-related access challenges are prevalent across many low- and middle-income countries (LMICs), product registration remains a critical regulatory gateway in Balaxis target markets. The markets addressed by the Company follow strict product regulations, making in-country registration essential for compliant, legal and sustained market entry.
The COVID 19 pandemic underscored the deep vulnerabilities of LMICs in accessing timely and affordable medicines, vaccines, and diagnostics. Latin America accounted for 28% of global COVID 19 deaths despite representing only 8% of global population. Post pandemic, there is increasing recognition among governments, multilateral agencies, and private sector participants of the need to build resilient, regionally diversified pharmaceutical supply chains.
Balaxis operating markets Angola in Africa, and Guatemala, Dominican Republic, Honduras, El Salvador, and Nicaragua in Latin America exhibited varied but broadly positive macroeconomic trajectories in CY2025, underpinned by sustained healthcare demand and continued pharmaceutical import growth.
Economic Growth - CY2025
| Market | CY2025 GDP Growth | GDP Nominal | Key Growth Driver | Outlook |
| Guatemala | 4.3% (4 year high) | ~$121 bn | Fiscal spending, remittances, exports | ~3.4% expected 2026 |
| Dominican Republic | ~1.9% | ~$121 bn | Tourism & services recovery | Rebound to ~3% in 2026\u201327 |
| Honduras | ~3.3% | ~$38 bn | Remittances, services | Stable ~3.4% forecast |
| El Salvador | ~4.3% | ~$35 bn | Government investment, dollarised stability | ~3.5\u20134.5% medium term |
| Nicaragua | ~3.1% | ~$15 bn | Agriculture and trade | Steady growth trajectory |
| Angola | ~2.1% | ~$80 bn | Non-oil sector; oil price headwinds | 2.1% in 2025\u201326; moderating |
| Ecuador* | 3.7% | ~$130 bn | Exports, investment, private consumption; non-oil exports and remittances | ~2.5% in 2026 and medium term |
| Chile* | 2.5% | ~$358 bn | Services, investment; large mining and energy projects | ~2.4% in 2026; ~2.3% medium term |
? Potential future markets for the company
Source: IMF World Economic Outlook, October 2025; World Bank Macro Poverty Outlook 2025; FocusEconomics Country Reports - Guatemala, Dominican Republic, Honduras, El Salvador, Nicaragua, Angola (2025 26); IMF Post Financing Assessment - Angola, September 2025
Latin America as a region represents a significant and growing pharmaceutical import market. The region imports five times more pharmaceuticals than it exports - making it structurally import dependent, which benefits suppliers with established local presence, product registration, and distribution infrastructure.
| Latin America pharmaceutical market estimated at ~US$97.8 billion in 2025, projected to reach US$172 billion by 2034 at ~6.5% CAGR | Guatemala: pharma imports estimated at ~$600 650 million in 2025; India is the largest single country supplier | Honduras: pharma imports approximately $350 400 million; India among top 5 suppliers |
| El Salvador: pharma imports approximately $620 660 million; strong demand for branded generics | Angola: pharmaceutical imports approximately $330 460 million; import dependent with ~95% of pharmaceuticals sourced externally | Indias pharma exports to Latin America grew 10% in FY26; to Angola grew 40% in FY25 \u2014 directly validating Balaxis geographic positioning |
Across Balaxis core markets, the regulatory environment for pharmaceutical approvals and registrations continued to evolve favourably in 2025, with several markets implementing streamlining measures that reduce barriers to market access for compliant players.
The regulatory maturation across Balaxis operating markets is structurally positive for established, compliant players. As registration pathways become more predictable and harmonisation across Central American markets deepens, Balaxis existing portfolio of 964 registered products represents an increasingly defensible competitive moat.
| Central America (LATAM) | Guatemala | Dominican Republic |
| Joint Mechanism for Drug Evaluation among Costa Rica, El Salvador, Guatemala, Honduras, and Nicaragua allows collaborative reliance \u2014 reducing registration time for cross market approvals | Regulatory reliance on EMA, USFDA, and Health Canada approvals accepted; strong regulatory infrastructure supports faster dossier processing for Indian standard products | Announced streamlining measures for generic drug approvals, following ANVISA model; branded generics approval pathway improved |
| El Salvador | Nicaragua | Angola (ARMED) |
| Pharmaceuticals regulated under the 2012 Medicine Law (DNM); continued improvements to registration infrastructure; reliance pathway active | First Spanish speaking country to recognise Indian Pharmacopoeia standards \u2014 materially enhancing credibility of Indian pharma manufacturers in LATAM | WHO supported Institutional Development Plan targeting Level 3 regulatory maturity by 2027; VAT exemption on healthcare imports maintained; liberalisation of distributor licensing underway |
Source: WHO Regional Office for Africa - Angola ARMED Institutional Development Plan, September 2025; DIA Global Forum - Regulatory Systems and Innovations in LAC, February 2025; Global Health Intelligence - Latin America Pharmaceutical Regulatory Update; Springer Nature / PMC - Comparison of LATAM Regulation Landscape; US Commercial Service - Angola Healthcare Guide; EU Trade Access - Health Sector in Central America
Demographic trends across Balaxis core markets reinforce the long term structural demand for affordable medicines. Both Latin America and Angola are undergoing significant demographic transitions that are reshaping healthcare spending patterns.
The healthcare access expansion in Balaxis markets is not a speculative trend - it is a structural consequence of rising household incomes, expanding insurance coverage in semi regulated markets, and increasing public health investment. For Balaxi, each incremental unit of healthcare spending in Guatemala, Angola, Honduras, or Nicaragua is a potential demand event for its registered product portfolio.
Ageing population in LATAM Median age rose from 18 (1950) to 31 (2024) and is forecast to reach 40 by 2050; elderly population growing 3x faster than total population, driving NCD therapy demand
Latin America total population 663 million people as of 2024; expanding middle class converting latent healthcare demand into active purchasing
Out of pocket expenditure 30 50% in Latin America vs 13% in high income countries; branded generics provide value proposition in cost sensitive markets where consumers pay directly
Healthcare spending growth (LAC) Per capita healthcare expenditure projected to grow at ~3.2% annually through 2050; economic growth and technology adoption are primary drivers
Disease burden shift Rising NCD prevalence (cardiovascular, diabetes, cancer) driving demand for long term formulations - directly aligned with Balaxis branded generics portfolio
Angola demographics Half of Angolas 36.7 million population is under 18; large demographic dividend potential; poverty remains high at ~31% driving demand for affordable generic medicines
Urban rural healthcare gap 21% of rural households in Latin America reported inability to access healthcare in 2020 - underpinning sustained demand for essential medicines in semi urban supply channels
Source: ECLAC - Demographic Observatory 2024; Inter American Development Bank (IDB) - Health Spending in Latin America and the Caribbean, 2025; J.P. Morgan Private Bank - Healthy Growth for Latin America, April 2025; World Bank - Angola Economic Update 2025; Lancet Regional Health Americas - Future Health Expenditures in LAC, 2025
India remains the worlds third largest pharmaceutical producer by volume and accounts for approximately 20% of global generic medicine demand. With the highest number of USFDA compliant manufacturing facilities outside the United States, India has established itself as the pharmacy of the world. In FY26, Indias pharmaceutical exports reached US$31.12 billion compared to US$30.47 billion in FY25 - growth of 2.13%. While slower than the 9.4% growth recorded in FY25, this was achieved against a challenging backdrop of global trade uncertainty, tariff related concerns, and Middle East supply chain disruptions.
| Total Pharma Exports | (US$ bn) |
| FY26 | 31.12 |
| FY25 | 30.47 |
| Growth | \u25b2 2.13% |
| Drug Formulations & Biologicals | (US$ bn) |
| FY26 | ~23.4 est. |
| FY25 | 22.93 |
| Growth | \u25b2 ~2% |
| Share of Formulations in Total Exports | |
| FY26 | ~75% |
| FY25 | 75.3% |
| Growth | \u25b2 Stable |
| Indias Share of Global Generic Supply | |
| FY26 | ~20% |
| FY25 | ~20% |
| Growth | \u25b2 Stable |
USFDA Compliant Plants outside US FY25: Highest globally FY26: Highest globally
Source: Pharmexcil (Pharmaceuticals Export Promotion Council of India) - Annual Export Data FY26; Ministry of Commerce & Industry, Govt. of India - DGCiS& Export Statistics; WHO - Prequalification Programme; USFDA - Foreign Inspection Database
The most significant structural development in Indias pharmaceutical export narrative in FY26 is the accelerating shift in growth from developed markets to frontier and emerging geographies. While the US remains the largest single market at approximately 34% of total exports, the pace of growth in Africa and Latin America has meaningfully outpaced the US in FY26.
| Region | FY25 Exports (US$ bn) | FY25 Growth | FY26 Trend | Share |
| North America (USA) | ~10.52 | +20.4% | ~Flat / Declining | ~34% |
| Africa (continent) | 3.93 | 0.4% | +13% | 12.9% |
| Latin America & Caribbean | 2.04 | +11.8% | +10% | 6.7% |
Source: Pharmexcil - India Pharma Export Data FY25 26; DGCiS - Country wise Pharma Exports; Ministry of Commerce, Govt. of India
The data above makes a compelling case: the two regions where Indias pharmaceutical exports grew fastest in FY26 - Africa as a continent (+13%, including Angolas 40% growth in FY25) and Latin America (+10%) - are precisely the frontier geographies where Balaxi Pharmaceuticals has built its business.
Latin America and the Caribbean have become one of the fastest growing export corridors for Indian pharmaceutical companies. Indias exports to the region reached US$2.04 billion in FY25, growing 11.8% year on year. In FY26, this momentum continued with estimated growth of approximately 10%, reflecting sustained demand for affordable generics, branded generics, and chronic care formulations.
| Guatemala: Indias pharma exports grew 17.6% in FY25 to US$99.6 million \u2014 Balaxis important LATAM market; CY2025 GDP grew 4.3%, a four year high | Dominican Republic: exports grew 22% to US$79 million \u2014 strong branded generics demand; streamlined regulatory approvals announced in 2025 | Honduras: Indias exports at US$32.2 million; El Salvador at US$35.6 million \u2014 both Balaxi growth markets |
| Nicaragua: recognised Indian Pharmacopoeia standards \u2014 the first Spanish speaking country to do so, enhancing Indian pharma credibility in LATAM | Ecuador and Chile identified as next expansion targets in the region, with combined pharma imports of significant scale |
Source: Pharmexcil/DGCI&S - India Countrywise Pharma Exports FY25; Ministry of Commerce, Govt. of India - Trade Statistics; FocusEconomics - Guatemala Country Report, April 2026
Angola is the only African market in which Balaxi currently operates and remains the companys largest single geography by revenue. Indias exports to Angola grew 40% in FY25 to US$84.3 million, reflecting both the scale of Angolas pharmaceutical import demand and the growth trajectory of Indian pharma in the country. Angolas pharmaceutical market is almost entirely import driven local manufacturing is negligible - with total pharma imports estimated at approximately US$330 460 million. The institutional and hospital segment, where Balaxi has been deepening its presence, carries specific working capital dynamics and payment cycle characteristics that require careful management.
Angolas CY2025 GDP growth moderated to approximately 2.1% (IMF), weighed by declining oil revenues and tightening external financing conditions. Inflation, though easing, remained elevated at 15.7% in December 2025 (down from a peak of 31.1% in July 2024). ARMEDs ongoing regulatory strengthening, with WHO technical support and a target of Level 3 maturity by 2027, is expected to improve market access predictability for compliant importers such as Balaxi.
| Angola Pharma Market Indicator | Data Point | Source / Period |
| Total pharmaceutical imports | ~US$ 330 460 mn | UN COMTRADE 2023 24 |
| Indias pharma exports to Angola | US$ 84.3 mn | DGCI&S FY25 |
| YoY growth in Indias Angola exports | +40.0% | DGCI&S FY25 vs FY24 |
| Angola GDP growth | ~2.1% | IMF WEO October 2025 |
| Angola CPI inflation | 15.7% (Dec 2025) | World Bank / National Bank of Angola |
| ARMED regulatory maturity target | Level 3 by 2027 | WHO Regional Office for Africa, Sep 2025 |
| Angola pharma market CAGR (forecast) | ~4.8% | 6Wresearch / Mobility Foresights 2024 2030 |
Source: UN COMTRADE - Angola Pharmaceutical Imports 2023 24; Pharmexcil / DGCI&S - India Countrywise Exports FY25; IMF Post Financing Assessment with Angola, September 2025; World Bank - Angola Country Page 2025; WHO Regional Office for Africa - Angola ARMED IDP Update, September 2025; 6Wresearch - Angola Pharmaceutical Market Report
Formulation led export basket Finished dosage products (tablets, capsules, liquids) - Balaxis core offering represent 75%+ of Indias pharma exports
Frontier market growth momentum Angola (+40% in FY25) and Latin America (+10% in FY26) are among Indias fastest growing markets, directly validating Balaxis geographic focus
Affordability advantage Indias cost efficient manufacturing supports competitive pricing in LATAM and Angola now reinforced by Balaxis own Jadcherla plant
Regulatory credibility WHO GMP, CDSCO compliance and increasing acceptance of Indian standards in LATAM markets; Nicaraguas Indian Pharmacopoeia recognition a milestone
Country specific execution Registration pipelines, local warehousing, and on ground commercial presence are competitive differentiators
Branded generics shift Growing acceptance of branded generics in semi regulated markets improves margin quality Balaxis 40% branded share positions it well
Balaxi Pharmaceuticals was built on an asset light commercial model acquiring product registrations, establishing local warehousing and distribution, and sourcing products from WHO GMP certified manufacturers in India and other markets. This model enabled rapid geographic expansion, capital efficiency, and the ability to replicate a tested market entry playbook across multiple frontier geographies over two decades. In FY26, the company completed the most significant milestone of this evolution: the commissioning and licensing of its first pharmaceutical formulation facility at Jadderha, Hyderabad.
| Asset Light era (2003\u20132024): Built market presence across 7 countries through registrations, warehousing, and distribution | Asset Right transition (FY25\u2013FY26): Commissioned first OSD manufacturing facility at Jadcherla \u2014 WHO GMP designed, Manufacturing Licence received in May, 2026 |
The Jadderha facility, located in a Pharma SEZ in Mahabubnagar, Telangana, is a purpose built oral solid dosage (OSD) manufacturing platform. It is designed to the standards of WHO GMP, CDSCO, and international norms, with a focus on producing tablets and capsules for Balaxis existing and targeted markets in Angola, Latin America and other target markets.
| FY26: Manufacturing Licence formally granted; plant qualification and validation complete; commercial production readiness achieved | Manufacturing + registrations + distribution = an integrated, harder to replicate competitive position |
| Facility Parameter | Detail |
| Location | Plot S 10, S 11 & S 12, Pharma SEZ, Jadderha, Mahabubnagar, Telangana |
| Total Land Area | 13,855 sq. m |
| Built up Area | 3,373 sq. m |
| Design Standard | WHO GMP, CDSCO, International Norms |
| Dosage Forms | Oral Solid Dosage \u2013 Tablets and Capsules |
| Granulation Capacity | 10 kg and 150 kg lines (wet and dry granulation) |
| Compression | Two double rotary 37 station compression machines |
| Packing Lines | 2 blister packing lines (PVC/Alu & Alu/Alu) + 1 strip packing line |
| QC Infrastructure | HPLC (2 units), FTIR, UV Spectrophotometry, Dissolution, Microbiology lab, Stability chambers |
| Regulatory Status | Manufacturing Licence received from Drug Control Administration, Govt. of Telangana; Plant Qualification and Validation complete |
| WHO GMP Certification | Targeted \u2013 process initiated; expected to open additional regulated market opportunities |
| Commissioning Status | Complete as of Q3 FY26; commercial production ready |
As of FY26, Balaxi operates across 6 countries Angola, Guatemala, Dominican Republic, Honduras, El Salvador, and Nicaragua (Latin America). The company manages 964 product registrations across these geographies, with over 200 additional registrations submitted or in the pipeline.
Angola
Market Stage Established
Key Characteristics Africas largest oil exporting economy; institutional and hospital market; high branded generics demand
FY26 Update Institutional channel transition underway; working capital cycle normalisation in progress
Guatemala
Market Stage Established
Key Characteristics Important LATAM market for Balaxi; high growth branded generics; strong regulatory infrastructure
FY26 Update Strong LATAM growth; drove 11% YoY LATAM revenue increase
Dominican Republic
Market Stage Established
Key Characteristics Semi regulated market; branded generics preference; new generic approvals streamlined in 2025
FY26 Update Positive momentum; 2025 regulatory tailwind
Honduras
Market Stage Growth
Key Characteristics Newer market; supply chain being scaled; expanding product registrations
FY26 Update Growing contribution to LATAM revenue
El Salvador
Market Stage Growth
Key Characteristics Positive commercial performance; strong branded generics demand
FY26 Update Increasing traction; part of LATAM growth story
Nicaragua
Market Stage Nascent
Key Characteristics Entered FY25; first Spanish speaking country to recognise Indian Pharmacopoeia
FY26 Update Registrations being secured; early stage
Honduras
Market Stage Growth
Key Characteristics Newer market; supply chain being scaled; expanding product registrations
FY26 Update Growing contribution to LATAM revenue
FY26 was the year Balaxi completed its most significant strategic investment: the commissioning and licensing of the Jadcherla pharmaceutical formulation facility. The Manufacturing Licence from the Drug Control Administration, Govt. of Telangana, was formally received during the year - a milestone that converts the facility from a capital project to a commercially operational asset.
| Plant Qualification and Validation: Complete as of Q3 FY26 \u2014 all equipment, utilities and systems qualified | Regulatory Status: Manufacturing Licence received from Drug Control Administration, Govt. of Telangana in May, 2026 | Stability Data: Initial batch stability data generated and found satisfactory \u2014 critical milestone for product release | Commercial Production: Ready to commence; immediate demand from existing markets in Angola and Latin America | WHO GMP Certification: Process initiated \u2014 targeted to open regulated market opportunities over medium term |
Latin America - Primary Growth EngineLATAM emerged as the key driver of top line growth in FY26, with revenue growing 11% YoY to 1111.29 crore. Guatemala, Dominican Republic, Honduras, El Salvador, and Nicaragua all contributed to this performance. Honduras and El Salvador, which entered commercial operations in FY24, continued to scale. New expansion initiatives were formally initiated in Ecuador and Chile - two meaningfully larger markets with higher per capita healthcare spending and greater branded generics acceptance.
Angola remains Balaxis primary market in Africa and the companys largest single geography by revenue. In FY26, Angolas performance was impacted by an extended working capital cycle in the institutional and hospital business segment - a channel where payment cycles are longer but per order values are materially higher. Management has taken steps to optimise working capital management, and normalisation is expected over the coming quarters.
964 Registered Products
200+ Pipeline / Filed Products
40% Branded Product Share
7 Geographies
49 New Registrations Added
Building Hardware Business DiscontinuationThe Company has initiated the process of discontinuing its ancillary Building Hardware business during FY26. This strategic decision is intended to sharpen focus on the core pharmaceutical business, improve working capital efficiency, and free up management bandwidth for pharmaceutical expansion. The discontinuation is expected to streamline the consolidated balance sheet and support future pharmaceutical growth.
| Revenue | |
| FY26 | 270.17 |
| FY25 | 292.56 |
| YoY Change | \u25bc (7.7%) |
| Gross Profit | |
| FY26 | 119.30 |
| FY25 | 126.86 |
| YoY Change | \u25bc (6.0%) |
| Gross Margin | % |
| FY26 | 44.2% |
| FY25 | 43.4% |
| YoY Change | \u25b2 +80 bps |
| EBITDA | |
| FY26 | 11.35 |
| FY25 | 33.50 |
| YoY Change | \u25bc (66.1%) |
| EBITDA Margin | % |
| FY26 | 4.2% |
| FY25 | 11.5% |
| YoY Change | \u25bc (725 bps) |
| Profit After Tax | |
| FY26 | 1.42 |
| FY25 | 25.07 |
| YoY Change | \u25bc (94.3%) |
| PAT Margin | % |
| FY26 | 0.5% |
| FY25 | 8.6% |
| YoY Change | \u25bc (805 bps) |
| Earnings Per Share | (\u20b9) |
| FY26 | 0.26 |
| FY25 | 4.54 |
| YoY Change | \u25bc (94.3%) |
FY26 revenue of 270.17 crore reflects strategic transition year dynamics - the working capital cycle extension in Angolas institutional channel created a near term drag, while LATAM delivered 11% growth. Gross margins improved 80 basis points to 44.2%, reflecting better business mix and disciplined product selection. EBITDA and PAT were materially impacted by Angola headwinds and non recurring Jadcherla commissioning costs.
| Category | Mix FY26 | Key Segments | Commentary |
| Geographies | Angola 52% LATAM 48% | Angola, CAR Guatemala, DR, Honduras, El Salvador, Nicaragua | LATAM share grew YoY; Angola includes institutional/hospital channel |
| Products | Branded 40% Generics 60% | Branded generics portfolio | Shift towards branded continues; pricing power building |
| Dosage Forms (Tablets) | 41% of total | Core OSD format | Aligned with Jadcherla facility focus |
| Therapeutic Areas | Antibiotics 41% Others 37% Analgesic 14% Anti malaria 8% | Essential medicines | Diversified across acute and chronic care |
| Sl. No. | Particulars | 31-03-2026 | 31-03-2025 |
| 1 | Current Ratio | 1.27 | 2.73 |
| 2 | Debt-Equity Ratio | 0.25 | 0.24 |
| 3 | Debt Service Coverage Ratio | 62.24 | 0 |
| 4 | Return on Equity Ratio | 47% | 33% |
| 5 | Inventory turnover ratio | 1,24,455.30 | 121.34 |
| 6 | Debtors Turnover Ratio / Trade Receivables turnover ratio | 1.05 | 0.73 |
| 7 | Trade payables turnover ratio | 5.19 | 4.78 |
| 8 | Net capital turnover ratio | 0.61 | 0.48 |
| 9 | Net profit ratio | 6.37% | 5.91% |
| 10 | Return on Capital employed | 7.24% | 5.71% |
| 11 | Interest Coverage Ratio | 3.61 | 3.57 |
| 12 | Operating Profit Margin | 12.03% | 12.04% |
| 13 | Return on Net Worth | 3.95% | 2.89% |
Explanations:
Current Ratio: The decrease in the Current Ratio from 2.73 to 1.27 is primarily attributable to cash being used for setting up manufacturing facility, resulting in lower current assets as on the reporting date.
Debt Service Coverage Ratio: Debt Service Coverage Ratio increased from not applicable in the previous year to 62.24 times in the current year. The ratio was not computed in the previous year as there was no long- term debt hence denominator (debt servicing obligation) was Nil, considering that the interest expense comprised Cash Credit interest and bill discounting interest.
Return on Equity Ratio: The Return on Equity Ratio increased from 33% to 47% primarily due to higher Profit After Tax during the current year, resulting in improved returns on shareholders equity.
Inventory Turnover Ratio: The Inventory Turnover Ratio increased significantly from 121.34 to 124,455.30 due to a substantially lower average inventory balance during the year. As the ratio is calculated using average inventory, the exceptionally low inventory level has resulted in a significantly higher turnover ratio.
Debtors Turnover Ratio / Trade Receivables Turnover Ratio: The Trade Receivables Turnover Ratio improved from 0.73 to 1.05 mainly due to improved collection efficiency and/or higher revenue from operations relative to average trade receivables during the year.
Net Capital Turnover Ratio: The Net Capital Turnover Ratio increased from 0.48 to 0.61 primarily due to improved revenue generation relative to the average working capital employed during the year.
Return on Capital Employed: The Return on Capital Employed increased from 5.71% to 7.24% mainly due to improved operating profitability, resulting in better utilization of capital employed.
Return on Net worth: The Return on net worth ratio has improved from 2.89% to 3.95% mainly because of increased profitability in the current year.
STRENGTHS
STRENGTHS- 964 registered products across 7 countries- significant regulatory moat built over 20 years- Captive OSD manufacturing facility at Jacherla - fully qualified, Manufacturing Licence received, ready for commercial production- Strong on ground distribution: 38 warehouses, owned vehicle fleets, 500+ professionals including 80+ expatriates- Branded generics leadership - 40% branded share improving margin profile; 44.2% gross margin in FY26- LATAM delivered 11% YoY revenue growth in FY26 to 111.29 crore- SAP ERP, digitalised regulatory workflows, and CRM tools for operational scalability- Indias low cost, WHO GMP certified manufacturing ecosystem as a sourcing and production advantage
OPPORTUNITIES
OPPORTUNITIES- Jadcherla facility to directly improve margins, reduce CMO dependence, and shorten product launch cycles; WHO GMP certification targeted- Ecuador and Chile expansion - larger, higher income LATAM markets with branded generics potential- South East Asia and CIS markets - replication of proven business model into new frontier geographies- Angola institutional channel normalisation - higher per order values as payment cycles normalise- Rising healthcare spending across LATAM and Angola - LATAM pharma market ~ 98 bn in 2025; Angola pharma imports ~ 460 mn- Discontinuation of Building Hardware business - improved capital efficiency and focus
WEAKNESSES
WEAKNESSES- Concentration risk significant revenue dependence on Angola- Working capital intensity in Angolas institutional/hospital channel - impacted FY26 margins- FY26 consolidated revenue declined 7.7% YoY to 270.17 crore- Currency exposure in markets with volatile exchange rates (AOA, GTQ)- Registration timelines of 12- 24 months create lags between market entry and revenue realisation- Limited presence in higher margin, faster growing LATAM markets like Brazil, Mexico, Colombia- Building Hardware ancillary business being discontinued - transition risk and management attention
THREATS
THREATS- Political instability and economic volatility in frontier markets (Angola GDP growth moderated to 2.1% in 2025)- Currency devaluation risk - Angola Kwanza precedent in FY24; AOA inflation still elevated at 15.7% end 2025- Intensifying competition from regional pharma players and global generics exporters in LATAM- Regulatory framework changes - registration delays, product dossier requirements evolving- Global supply chain disruptions - logistics route risks (Middle East, port congestion)- Delays in Angolas institutional payment cycles - near term risk in hospital channel- US tariff uncertainty and global trade headwinds dampening remittances to Central America, pressuring consumer spending
| Risk Category | Probability | Impact | Mitigation Approach |
| Regulatory Compliance & Market Access | Moderate | High | Dedicated regulatory teams; digitised workflows; proactive engagement; 12-24 month pipeline monitoring |
| Currency Fluctuation (AOA, GTQ) | High | High | Regular financial reviews; pricing strategy adjustments; Angola experience has strengthened FX risk processes |
| Supply Chain Disruption | Low-Moderate | Moderate-High | Jadcherla facility reduces CMO dependence; diversified supplier base (India, China, Portugal); buffer stocks across 38 warehouses |
| Competitive Market Dynamics | High | Moderate-High | Brand building and branded generics shift creates pricing power; on ground teams with deep market relationships |
| Geopolitical and Economic Factors | Moderate-High | Moderate-High | Multi country diversification (8 markets); established local stakeholder relationships; scenario planning |
| Angola Working Capital & Payment Cycles | Moderate | Moderate | Institutional channel payment cycle management; SAP based receivables tracking; channel mix optimisation |
| Manufacturing & Compliance Risk (Jadcherla) | Low | Moderate-High | WHO GMP/CDSCO design standards; qualified and validated systems; dedicated quality head; WHO GMP certification targeted |
| Angola Kwanza Currency Risk | Moderate | High | Pricing strategy adapted post FY24 experience; inflation easing (15.7% Dec 2025 vs 31.1% Jul 2024); ongoing monitoring |
Balaxi Pharmaceuticals enters FY27 at an inflection point. The commissioning and licensing of the Jadcherla facility marks the completion of the most capital intensive phase of the companys evolution. The investments made in manufacturing, registrations, distribution infrastructure, and digital systems over the past few years are now positioned to generate returns.
| Strategic Priority | Expected Outcome | Timeframe |
| Jadcherla commercial production | Margin improvement; reduced CMO dependence; faster product launches; access to other regulated markets | H1 FY27 |
| Angola institutional channel normalisation | Working capital optimisation; improved cash flow; stronger EBITDA contribution | H1-H2 FY27 |
| LATAM expansion \u2013 Ecuador and Chile | New revenue streams; portfolio registration growth in larger, higher income markets | FY27-FY28 |
| Building Hardware business discontinuation | Improved capital efficiency; management focus on pharma core business | FY27 |
| Product portfolio branded share increase | Higher gross margins; improved price realisation; physician loyalty building | Ongoing |
| New market entry planning | Next phase of geographic diversification using proven business model | FY27-FY28 |
| WHO GMP certification for Jadcherla | Opens regulated market filing opportunities; enhances institutional procurement credentials | FY27 |
The structural tailwinds supporting Balaxis business model - rising healthcare access in LATAM and Angola, Indias growing frontier market export momentum, the branded generics shift in semi regulated markets, accelerating regulatory maturation in operating markets, and increasing recognition of the supply gap in essential medicines - are durable and multi year in nature. Balaxis integrated platform of manufacturing, registrations, and distribution is uniquely positioned to capitalise on these tailwinds and build sustainable long term value.
Certain statements in this section and elsewhere in this Management Discussion & Analysis may be forward looking statements. Such statements are subject to risks and uncertainties, including regulatory changes, local political or economic developments, currency fluctuations, and other factors that could cause actual results to differ materially from those contemplated. Balaxi Pharmaceuticals Limited undertakes no obligation to publicly update or revise any forward looking statements.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
